Metabolic Effects of Isradipine In Normotensive NIDDM Patients With Microalbuminuria

631 Abstract: The aim of this study was to determine whether isradipine affects microalbuminuria and other biochemical parameters related to glucose and lipid metabolisms. 18 subjects, 40 to 73 years of age, with NIDDM for 0 to 21 years, blood pressure≤140/90 mmHg in the absence of antihypertensive treatment, and persistent urinary albumin excretion rate (UAER) 30 to 300 mg/day, received sustained-release (SRO) formulation isradipine at dosages of 5 mg once daily for 3 months. The effects of isradipine on microalbuminuria, fasting plasma glucose, plasma lipids, plasma creatinin, uric acid, C-peptide, insulin, HbA 1c , fructosamine, systolic and diastolic blood pressure and heart rate were assayed. After 3 months of isradipine treatment, UAER fell from 72.5±40.2 to 52.9±39.5 mg/24 h (p<0.01). Diastolic blood pressure decreased from 85.8±4.9 to 81.9±3.0 mmHg (p<0.05). Other parameters were not significantly influenced by isradipine treatment. After 3 months of therapy, isradipine regressed diabetic nephropathy in normotensive NIDDM patients. No serious clinical or metabolic side effects were observed.